166 related articles for article (PubMed ID: 35979119)
1. Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.
Hojo N; Nagasaki M; Mihara Y
World J Clin Cases; 2022 Jun; 10(17):5708-5716. PubMed ID: 35979119
[TBL] [Abstract][Full Text] [Related]
2. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
Wang L; Wang W; Li X; Guo Y; Zhu X
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
[TBL] [Abstract][Full Text] [Related]
3. Unraveling the Mystery of Gray Zone Lymphoma in Human Immunodeficiency Virus-Seropositive Patients: Two Cases.
Ahluwalia A; Bondili L; Salamera J; Cholankeril M
J Hematol; 2020 Dec; 9(4):132-136. PubMed ID: 33224393
[TBL] [Abstract][Full Text] [Related]
4. A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.
Mallipudi RM; Alquran L; Shenoy VA; Leslie LA; Conti JA
Case Rep Oncol Med; 2019; 2019():4121234. PubMed ID: 31110830
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
Pilichowska M; Pittaluga S; Ferry JA; Hemminger J; Chang H; Kanakry JA; Sehn LH; Feldman T; Abramson JS; Kritharis A; Hernandez-Ilizaliturri FJ; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA; Jagadeesh D; Woda B; Gupta GK; Gascoyne RD; Jaffe ES; Evens AM
Blood Adv; 2017 Dec; 1(26):2600-2609. PubMed ID: 29296913
[TBL] [Abstract][Full Text] [Related]
7. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
8. B Cell Lymphoma, Unclassifiable, Transformed from Follicular Lymphoma: A Rare Presentation with Review of the Literature.
Kanna A; Agrawal S; Jayant K; Kumar Pala V; Altujjar M; Hadid T; Khurram M
Case Rep Hematol; 2015; 2015():651764. PubMed ID: 26380128
[TBL] [Abstract][Full Text] [Related]
9. How I manage patients with grey zone lymphoma.
Kritharis A; Pilichowska M; Evens AM
Br J Haematol; 2016 Aug; 174(3):345-50. PubMed ID: 27301470
[TBL] [Abstract][Full Text] [Related]
10. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
Wang E; Papavassiliou P; Sebastian S
Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
[TBL] [Abstract][Full Text] [Related]
11. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.
Bischin AM; Dorer R; Aboulafia DM
Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851
[TBL] [Abstract][Full Text] [Related]
12. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
13. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma without mediastinal disease: mimicking nodular sclerosis classical Hodgkin lymphoma.
Iwaki N; Sato Y; Kurokawa T; Maeda Y; Ohno K; Takeuchi M; Takata K; Orita Y; Nakao S; Yoshino T
Med Mol Morphol; 2013 Sep; 46(3):172-6. PubMed ID: 23512149
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report.
Asrani R; Cengiz TB; Petersen BE; Anagnostou T; Brody JD
Front Oncol; 2023; 13():1254256. PubMed ID: 38313213
[TBL] [Abstract][Full Text] [Related]
15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
17. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.
Sarkozy C; Copie-Bergman C; Damotte D; Ben-Neriah S; Burroni B; Cornillon J; Lemal R; Golfier C; Fabiani B; Chassagne-Clément C; Parrens M; Herbaux C; Xerri L; Bossard C; Laurent C; Cheminant M; Cartron G; Cabecadas J; Molina T; Salles G; Steidl C; Ghesquières H; Mottok A; Traverse-Glehen A
Am J Surg Pathol; 2019 Mar; 43(3):341-351. PubMed ID: 30540571
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
19. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
